

U.S. Patent Application No. ~~09/564,288~~ 09 613 038
Amendment and Reply dated February 8, 2007

RECEIVED
CENTRAL FAX CENTER
FEB 08 2007

Amendment to the Claims:

Please amend the claims as follows:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-5. (Cancelled)

6. (Currently amended) The method of claim [[1]] 45 wherein the antibody is not conjugated with a cytotoxic agent.

7. (Cancelled))

8. (Currently amended) The method of claim [[1]] 45 wherein the antibody is conjugated with a cytotoxic agent.

9. (Original) The method of claim 8 wherein the cytotoxic agent is a radioactive compound.

10. (Previously presented) The method of claim 9 wherein the antibody comprises Y2B8 or ¹³¹I-B1.

Claims 11-15. (Cancelled)

16. (Currently amended) The method of claim [[1]] 45 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m² dose of the antibody in the subsequent dose exceeds the mg/m² dose of the antibody in the initial dose.

Claims 17-21. (Cancelled)

22. (Currently amended) The method of claim [[1]] 45 comprising administering the antibody to the human before the human is exposed to the graft.

U.S. Patent Application No. 09/564,288
Amendment and Reply dated February 8, 2007

Claims 23-31. (Cancelled)

32. (Previously presented) The method of claim 10, wherein the antibody comprises Y2B8.

33. (Previously presented) The method of claim 10, wherein the antibody comprises ¹³¹I-B1.

34. (Currently amended) The method of claim ~~[[1]]~~ 45, wherein the antibody is a human antibody.

Claims 35-36. (Cancelled)

37. (Currently amended) The method of claim ~~[[28]]~~ 46, wherein the antibody is a human antibody.

Claims 38-40. (Cancelled)

41. (Currently amended) The method of claim ~~[[28]]~~ 46, wherein the antibody comprises Y2B8.

Claims 42-44. (Cancelled)

45. (Previously presented) A method of blocking an immune response to an allogeneic graft in a human, where the human is not suffering from a malignancy, consisting essentially of administering to the human more than one dose of a therapeutically effective amount of an antibody which binds to the CD20 antigen on human B lymphocytes, wherein each administration of the antibody is by intravenous injection.

46. (Previously presented) A method of treating graft-versus-host or host-versus-graft disease in a human, wherein the graft is from a human having the same or a different genetic origin as the human being treated, consisting essentially of administering intravenously

U.S. Patent Application No. 09/564,288
Amendment and Reply dated February 8, 2007

to the human more than one dose of a therapeutically effective amount of an antibody which binds to the CD20 antigen on human B lymphocytes, wherein each administration of the antibody is by intravenous injection.

47. (Previously presented) The method of claim 45, wherein the antibody is a chimeric antibody.

48. (Previously presented) The method of claim 45, wherein the antibody is a humanized antibody.

49. (Previously presented) The method of claim 45, wherein the antibody is rituximab.

50. (Previously presented) The method of claim 45, wherein each dose is in the range from about 20mg/m^2 to about 1000mg/m^2 of the antibody to the human.

51. (Previously presented) The method of claim 45, wherein each dose of the antibody is substantially less than 375 mg/m^2 .

52. (Previously presented) The method of claim 45 wherein each dose is in the range from about 20mg/m^2 to about 250mg/m^2 .

53. (Previously presented) The method of claim 45 wherein each dose is in the range from about 50mg/m^2 to about 200mg/m^2 .

54. (Previously presented) The method of claim 46, wherein the antibody is a chimeric antibody.

55. (Previously presented) The method of claim 46, wherein the antibody is a humanized antibody.

U.S. Patent Application No. 09/564,288
Amendment and Reply dated February 8, 2007

56. (Previously presented) The method of claim 46, wherein the antibody is rituximab.
57. (Previously presented) The method of claim 46, wherein each dose is in the range from about $20\text{mg}/\text{m}^2$ to about $1000\text{mg}/\text{m}^2$ of the antibody to the mammal.
58. (Previously presented) The method of claim 46, wherein each dose of the antibody is substantially less than $375\text{ mg}/\text{m}^2$.
59. (Previously presented) The method of claim 46 wherein each dose is in the range from about $20\text{mg}/\text{m}^2$ to about $250\text{mg}/\text{m}^2$.
60. (Previously presented) The method of claim 46 wherein each dose is in the range from about $50\text{mg}/\text{m}^2$ to about $200\text{mg}/\text{m}^2$.
61. (Cancelled)
62. (New) A method of blocking an immune response to an allogeneic graft in a human, where the human is not suffering from a malignancy, comprising administering to the human more than one dose of a therapeutically effective amount of an antibody which binds to the CD20 antigen on human B lymphocytes, wherein each administration of the antibody is by intravenous injection.
63. (New) A method of treating graft-versus-host or host-versus-graft disease in a human, wherein the graft is from a human having the same or a different genetic origin as the human being treated, comprising administering intravenously to the human more than one dose of a therapeutically effective amount of an antibody which binds to the CD20 antigen on human B lymphocytes, wherein each administration of the antibody is by intravenous injection.